Cymbalta caused dangerous skin condition, lawsuit says 
Published: January 30, 2012
Tags: Cymbalta, defective design, drug litigation, Eli Lilly, FDA, Food and Drug Administration, Stevens-Johnson Syndrome, strict liability
A Kansas woman has filed a product liability suit against Eli Lilly, claiming she suffered a life-threatening skin condition known as Stevens-Johnson syndrome as a result of taking the drug company’s anti-depressant Cymbalta.
Glaxo, U.S. reach tentative $3B deal over Avandia
Published: November 17, 2011
Tags: Avandia, Department of Justice, diabetes, drug litigation, GlaxoSmithKline, off-label uses
GlaxoSmithKline has announced a tentative deal with the federal government under which the drug company would pay a record $3 billion to end an investigation into the marketing of Avandia for “off-label” uses.
Deadline approaches for certain fen-phen claims
Published: August 29, 2011
Tags: class action, drug litigation, fen-phen
A Dec. 31, 2011 deadline in the fen-phen litigation faces certain individuals who may be eligible for additional cash payments from the $4.8 billion nationwide class settlement involving the recalled diet drug.
Darvon, Darvocet liability suits consolidated in federal court
Published: August 26, 2011
Tags: Darvocet, Darvon, drug litigation, MDL, multidistrict litigation
A federal judicial panel has consolidated product liability suits involving the popular pain medications Darvon and Darvocet in the U.S. District Court for the Eastern District of Kentucky.
FDA: New label for anti-smoking drug Chantix
Published: August 9, 2011
Tags: black box warning, Chantix, drug labeling, drug litigation, FDA, Food and Drug Administration, smoking
The Food and Drug Administration has announced that the label for the smoking cessation drug Chantix will be updated to address the effect of the drug on users with cardiovascular disease.
Discovery expanded in Yaz, Yasmin multidistrict litigation
Published: August 3, 2011
Tags: Bayer, birth control, Discovery, drug litigation, failure to warn, MDL, multidistrict litigation, Yasmin, Yaz
Discovery in the multidistrict litigation over the birth control drugs Yaz/Yasmin has been expanded beyond the 24 selected bellwether cases.
Panel weighs consolidation of Darvon/Darvocet litigation
By:
Sylvia Hsieh
Published: July 29, 2011
Tags: Darvocet, Darvon, drug litigation, Eli Lilly, MDL, multidistrict litigation, PLIVA v. Mensing
SAN FRANCISCO – In oral arguments before the multidistrict litigation panel on Thursday in San Francisco, lawyers sparred over whether litigation involving the popular pain medications Darvon and Darvocet should be consolidated and if so, where they should be centralized.
In drug tort suits, it’s a name game
By:
Kimberly Atkins
Published: July 5, 2011
Tags: drug litigation, generic drugs, preemption, Supreme Court
WASHINGTON – The Supreme Court ruling late last month that state-law failure-to-warn claims against generic drug makers are preempted by federal law – handed down just two years after the Court held that brand-name drug makers could face such suits – creates a legal discrepancy that leaves the majority of patients without recourse, some advocates say.
Plaintiff wins verdict over contaminated Heparin
Published: June 30, 2011
Tags: Baxter, drug litigation, Heparin
An Illinois jury has awarded $625,000 to the estate of a man who died after being given a contaminated form of the blood thinner Heparin during dialysis.
Generic drug failure-to-warn claims ruled preempted
Published: June 23, 2011
Tags: drug litigation, generic drugs, metoclopramide, preemption, Supreme Court, tardive dyskinesia
Federal drug regulations governing generic drugs directly conflict with, and thus preempt, state-law failure-to-warn claims, the U.S. Supreme Court has ruled.
SUBSCRIBERS: Did you receive the new Lawyers USA Weekly Update in your inbox on Monday?
If not, click here to register and learn more now.
